Phase 2 N=82 Effect of Galantamine on Short-term Abstinence
Tobacco Use Disorder
Primary: Total Number of Smoke-free Days (Biochemically Verified) During a 7-day Quit Attempt. — 3.6; 3.7 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential Tremor
Essential Tremor
Primary: Mean TRS (Tremor Rating Score) — 26.6; 27.6 units on a scale
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Phase 3 N=203 Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Acute Alcoholic Hepatitis
Primary: Overall Survival — 57; 66 Participants — p=0.904
N/A N=113 The Effect of Hypovitaminosis D and Vitamin D Supplementation on Fracture Nonunion Rates
Hypovitaminosis D
Primary: Fracture Union — 40; 39; 10 Participants
Phase 4 N=346 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
Irritable Bowel Syndrome With Diarrhea
Primary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores — 22.7…
Phase 1 N=88 Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 0; 16.7; 33.3; 16.7 percentage of participants
N/A N=84 Accommodative Relief for Uncomfortable Non-Presbyopes
Asthenopia
Primary: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score — 14.3; 12.8; 19.0 scores on a scale — p=<0.001
Phase 2 N=425 Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass
Cardiac Surgery · Cardiopulmonary Bypass
Primary: Percentage of Subjects With Any Component of a Major Morbidity Composite — 68; 58 Participants
N/A N=1,997 Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)
Patients Indicated for an ICD
Primary: Percentage of Subjects Who Are Free of Complications Related to the Linox ICD Lead — 90.9 percentage of subjects — p=0.0020
Phase 1 N=11 Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)
Osteoarthritis, Knee
Primary: Adverse Events — 27; 1 events
Phase 1 N=63 Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Primary: At Least 1 TEAE — 2; 12; 12; 12 Participants
N/A N=20 Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
Colorectal Carcinoma
Primary: Freedom From Serious Adverse Events Rate — 18 Participants
Phase 3 N=512 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
Amyotrophic Lateral Sclerosis
Primary: Overall Survival Rate at 18 Months — 67.5; 69.4 percentage of partcipants — p=0.71
N/A N=136 Study of Exercise Training in Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic
Primary: Change in Peak Oxygen Consumption (Peak VO2) — 1.35; 0.08 mL/kg/min